Fluoropyrimidines in the treatment of advanced neoplastic diseases: Role and advantages of UFT

Michele Del Vecchio, Giuseppe Procopio, Antonino Cassata, Paola Pozzi, Giuseppina Busto, Luigi Celio, Emilio Bajetta

Research output: Contribution to journalArticle

Abstract

The fluoropyrimidine antimetabolites were employed in a wide range of neoplastic diseases. In particular, 5-fluorouracil in association with other chemotherapeutic agents, or biochemical modulators was successfully used in the treatment of colorectal, gastric, breast, head and neck cancers. With this type of chemotherapy, a response rate ≤ 20% was obtained in gastrointestinal tumors, without a statistically significant impact on the overall survival. UFT is a combination of tegafur an uracil, which has the important advantage of an improved oral bioavailability, if we compare it with 5-fluorouracil. Uracil, avoiding the fluoropyrimidine degradation inside the tumor cells, increases the permanence of the metabolically active fluropyrimidine into the target cell, so having an improvement in the therapeutic activity. A very large spectrum of cancers were treated with this molecule. In particular, a response rate in the range of 20-40% was observed in the treatment of patients with metastatic colorectal cancer. Phase III trials are ongoing to evaluate the advantage on 5-FU of this new fluoropyrimidine in terms of clinical efficacy, and quality of life, considering the possibility to administer it orally.

Original languageEnglish
Pages (from-to)6-11
Number of pages6
JournalTumori
Volume85
Issue number1
Publication statusPublished - Jan 1999

Fingerprint

Fluorouracil
Uracil
Colorectal Neoplasms
Tegafur
Antimetabolites
Neoplasms
Head and Neck Neoplasms
Biological Availability
Stomach Neoplasms
Therapeutics
Quality of Life
Breast Neoplasms
Drug Therapy
Survival

Keywords

  • Chemotherapy
  • Colorectal cancer
  • Fluoropyrimidines

ASJC Scopus subject areas

  • Cancer Research

Cite this

Fluoropyrimidines in the treatment of advanced neoplastic diseases : Role and advantages of UFT. / Del Vecchio, Michele; Procopio, Giuseppe; Cassata, Antonino; Pozzi, Paola; Busto, Giuseppina; Celio, Luigi; Bajetta, Emilio.

In: Tumori, Vol. 85, No. 1, 01.1999, p. 6-11.

Research output: Contribution to journalArticle

@article{04f5fc11b71e4f4a9d88241da87a5eb9,
title = "Fluoropyrimidines in the treatment of advanced neoplastic diseases: Role and advantages of UFT",
abstract = "The fluoropyrimidine antimetabolites were employed in a wide range of neoplastic diseases. In particular, 5-fluorouracil in association with other chemotherapeutic agents, or biochemical modulators was successfully used in the treatment of colorectal, gastric, breast, head and neck cancers. With this type of chemotherapy, a response rate ≤ 20{\%} was obtained in gastrointestinal tumors, without a statistically significant impact on the overall survival. UFT is a combination of tegafur an uracil, which has the important advantage of an improved oral bioavailability, if we compare it with 5-fluorouracil. Uracil, avoiding the fluoropyrimidine degradation inside the tumor cells, increases the permanence of the metabolically active fluropyrimidine into the target cell, so having an improvement in the therapeutic activity. A very large spectrum of cancers were treated with this molecule. In particular, a response rate in the range of 20-40{\%} was observed in the treatment of patients with metastatic colorectal cancer. Phase III trials are ongoing to evaluate the advantage on 5-FU of this new fluoropyrimidine in terms of clinical efficacy, and quality of life, considering the possibility to administer it orally.",
keywords = "Chemotherapy, Colorectal cancer, Fluoropyrimidines",
author = "{Del Vecchio}, Michele and Giuseppe Procopio and Antonino Cassata and Paola Pozzi and Giuseppina Busto and Luigi Celio and Emilio Bajetta",
year = "1999",
month = "1",
language = "English",
volume = "85",
pages = "6--11",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Fluoropyrimidines in the treatment of advanced neoplastic diseases

T2 - Role and advantages of UFT

AU - Del Vecchio, Michele

AU - Procopio, Giuseppe

AU - Cassata, Antonino

AU - Pozzi, Paola

AU - Busto, Giuseppina

AU - Celio, Luigi

AU - Bajetta, Emilio

PY - 1999/1

Y1 - 1999/1

N2 - The fluoropyrimidine antimetabolites were employed in a wide range of neoplastic diseases. In particular, 5-fluorouracil in association with other chemotherapeutic agents, or biochemical modulators was successfully used in the treatment of colorectal, gastric, breast, head and neck cancers. With this type of chemotherapy, a response rate ≤ 20% was obtained in gastrointestinal tumors, without a statistically significant impact on the overall survival. UFT is a combination of tegafur an uracil, which has the important advantage of an improved oral bioavailability, if we compare it with 5-fluorouracil. Uracil, avoiding the fluoropyrimidine degradation inside the tumor cells, increases the permanence of the metabolically active fluropyrimidine into the target cell, so having an improvement in the therapeutic activity. A very large spectrum of cancers were treated with this molecule. In particular, a response rate in the range of 20-40% was observed in the treatment of patients with metastatic colorectal cancer. Phase III trials are ongoing to evaluate the advantage on 5-FU of this new fluoropyrimidine in terms of clinical efficacy, and quality of life, considering the possibility to administer it orally.

AB - The fluoropyrimidine antimetabolites were employed in a wide range of neoplastic diseases. In particular, 5-fluorouracil in association with other chemotherapeutic agents, or biochemical modulators was successfully used in the treatment of colorectal, gastric, breast, head and neck cancers. With this type of chemotherapy, a response rate ≤ 20% was obtained in gastrointestinal tumors, without a statistically significant impact on the overall survival. UFT is a combination of tegafur an uracil, which has the important advantage of an improved oral bioavailability, if we compare it with 5-fluorouracil. Uracil, avoiding the fluoropyrimidine degradation inside the tumor cells, increases the permanence of the metabolically active fluropyrimidine into the target cell, so having an improvement in the therapeutic activity. A very large spectrum of cancers were treated with this molecule. In particular, a response rate in the range of 20-40% was observed in the treatment of patients with metastatic colorectal cancer. Phase III trials are ongoing to evaluate the advantage on 5-FU of this new fluoropyrimidine in terms of clinical efficacy, and quality of life, considering the possibility to administer it orally.

KW - Chemotherapy

KW - Colorectal cancer

KW - Fluoropyrimidines

UR - http://www.scopus.com/inward/record.url?scp=0032967648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032967648&partnerID=8YFLogxK

M3 - Article

C2 - 10228489

AN - SCOPUS:0032967648

VL - 85

SP - 6

EP - 11

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 1

ER -